In the PEBC Pharmacist Qualifying Examination Part II, you apply pharmacist knowledge through short practical tasks. A useful response connects the patient's account, medication record and clinical findings to a safe action you can explain. For example, a reported “allergy” may be an intolerable adverse effect, a discharge list may conflict with what the patient actually takes, and a technically correct label may still conceal an unsuitable prescription. This guide develops those distinctions through Canadian pharmacist scenarios. It follows care from information gathering and therapy assessment to dispensing, collaboration and follow-up. It also covers evidence-informed judgment, public health and professional obligations. In every case, identify what matters for this patient, resolve the immediate problem and make the next step clear.
Providing Care: Clinical Care
1. Build the medication history
A medication history describes what the patient actually uses, including prescription medicines, nonprescription products, supplements, and medicines taken only when needed. Start with an open invitation to describe a usual day, then ask about names, strengths, amounts, timing, purpose, recent changes, and missed doses. Compare the account with at least one other source, such as containers, a dispensing record, or a discharge list. A dispensing record shows what was supplied; it cannot prove what was swallowed. Record the source and confidence for each entry, and keep disagreements visible until resolved. This PEBC Qualifying Examination guide can help place the history task within the broader pharmacist pathway. In practice, the history becomes the baseline for assessing therapy and reconciling changes.
Worked example: A patient says, “I take metformin once each morning.” The dispensing record shows instructions for morning and evening use. Record the morning dose as patient-confirmed and the evening dose as unresolved, with the record as its source. Ask to see the bottle and whether a prescriber changed the directions. Until verified, do not describe the patient as taking two daily doses.
Watch the distinction: A recent refill is evidence of supply, not adherence. Treating its label as the current regimen can hide a patient’s deliberate change or misunderstanding.
2. Clarify an allergy label
An allergy entry is useful only when its reaction history is clear. Ask which medicine was involved, what happened, how soon after exposure it began, whether treatment was needed, and whether the person has tolerated that medicine or a related one since. Hives, swelling, wheeze, or circulatory symptoms raise concern for an immediate immune-type reaction; isolated nausea is often a predictable adverse effect. Timing and symptoms matter more than the patient’s chosen label. An unknown childhood reaction should remain uncertain rather than being recast as harmless. Record the reaction and its severity in plain language, then assess the proposed medicine against that history. This preserves safety while avoiding an unnecessarily broad allergy label that could restrict suitable treatment.
Worked example: A patient reports “codeine allergy” after becoming nauseated on the first day of treatment. They recall no rash, swelling, wheeze, or breathing difficulty and needed no emergency care. Record “codeine: nausea, severity and dose to confirm” as a reported adverse effect. Ask how severe the nausea was and assess the proposed alternative for its own benefits and harms before supplying it.
Watch the distinction: Calling every unpleasant effect an allergy obscures the actual risk. Conversely, a vague label should not be dismissed when the patient cannot recall the reaction.
3. Reconcile medicines after discharge
Medication reconciliation compares three views of treatment: what the patient took before admission, what the discharge orders intend, and what the patient is taking now. Mark each medicine as continued, changed, started, or stopped, then investigate any mismatch. The central question is whether a difference was intentional, not which list looks newest. High-risk duplication deserves immediate attention because a patient can follow two individually plausible instructions and still be harmed. Contact the discharging team or another authoritative source to confirm the intended transition, communicate the verified regimen in usable terms, and update the pharmacy record. The NAPRA pharmacist competencies identify medication reconciliation as part of pharmacist clinical assessment.
Worked example: A discharge list starts apixaban, but the patient says they took their usual warfarin this morning and plan to continue it. Identify possible duplicate anticoagulation and ask about bleeding symptoms, the last warfarin dose, and the discharge instructions. Urgently confirm the transition with the discharging team. Give the patient the confirmed instructions before further use and document the discrepancy, contact, and outcome.
Watch the distinction: Do not infer that a new anticoagulant automatically cancels every old instruction. The intended start and stop times require confirmation before advising the patient.
4. Use a focused clinical assessment
A focused assessment gathers enough information to choose a safe next action. Establish onset and progression, symptom severity, relevant exposures, existing illness, medicines, and what the patient has already tried. Ask targeted questions that distinguish a minor self-limited problem from one requiring urgent assessment. For cough, breathing difficulty, chest pain, concerning fever, or worsening condition changes the decision more than a preference for a particular cough product. Observe what is available in the encounter, such as ability to speak comfortably, but avoid claiming a diagnosis from limited pharmacy findings. Explain the concern and the urgency in ordinary language, arrange appropriate assessment, and pass on the key findings. Product advice can follow only if immediate safety has been addressed.
Worked example: A patient asks for cough syrup. They report fever, increasing shortness of breath, and chest pain that is getting worse. Ask when symptoms began, whether the pain or breathlessness is present now, and whether they can travel safely. Explain that these symptoms need urgent medical assessment, help arrange it, and relay the findings. Do not delay that action to compare cough products.
Watch the distinction: A familiar symptom such as cough does not make the whole presentation minor. Red flags and deterioration determine urgency, even when the patient requests routine self-care.
5. Classify medication therapy problems
Classifying a medication therapy problem helps identify what must change. An untreated indication lacks needed therapy; wrong-drug selection means the chosen agent does not fit the patient or condition. An ineffective dose supplies too little useful exposure, while an excessive dose creates unnecessary exposure. An adverse reaction is harm caused by a medicine; an interaction arises when another drug, food, disease, or test changes its effect or interpretation. Non-adherence describes medicine use that differs from the agreed regimen. No indication means a medicine lacks a valid current purpose. These categories can overlap, so name the immediate concern and its cause separately. For duplicate medicines, first confirm whether both were deliberately prescribed for distinct purposes, then resolve the unnecessary treatment and its supply.
Worked example: After a hospital switch, a patient has continued omeprazole and pantoprazole at home. Both are proton pump inhibitors, and the available records show one acid-suppression indication. Classify this as possible therapy without an additional indication, with duplicate exposure. Verify which medicine the discharge team intended, stop the extra supply according to that confirmed plan, and update the patient’s list.
Watch the distinction: Two medicines in the same class are not automatically an overdose. Identify the intended indications and regimen before assigning the problem and changing therapy.
6. Assess kidney function in context
A creatinine result reflects kidney filtration imperfectly and must be read with its previous value, timing, hydration, and medicines. A rapid rise during vomiting suggests an acute change rather than a stable chronic baseline. Reduced fluid volume can lower kidney blood flow. An ACE inhibitor reduces pressure within the kidney’s filtering units, while a diuretic can add to fluid loss; together they may worsen filtration during an acute illness. Ask about oral intake, urine output, dizziness, and other potentially kidney-affecting medicines. Arrange timely clinical evaluation and a medication plan appropriate to the illness and local authority. A single creatinine value cannot establish the cause or the patient’s usual kidney function, so avoid making a routine long-term dose decision from it alone.
Worked example: A patient taking ramipril and a diuretic has been vomiting for two days. Creatinine has risen from 80 to 150 micromol/L, an increase of 70 micromol/L, or 87.5% of baseline. Ask about fluid intake, urine output, and dizziness. Treat possible acute kidney injury as time-sensitive, arrange clinical evaluation and repeat testing, and clarify interim medicine instructions with the care team.
Watch the distinction: The latest creatinine is not simply a new stable baseline. Its change during illness can signal acute harm, even before the cause is known.
7. Recognize drug-related hyperkalemia
Potassium balance depends heavily on kidney excretion. Ramipril reduces aldosterone signaling, and spironolactone blocks aldosterone’s action; both can reduce potassium loss in urine. The combination may be appropriate for some patients, but kidney function, dose changes, potassium supplements, and illness alter its safety. Interpret a result against the supplied laboratory range and the patient’s symptoms, then verify whether the sample could have been affected by collection or handling. Weakness, palpitations, fainting, or an abnormal heart rhythm raises urgency. An elevated result should trigger prompt assessment of the intended regimen and current kidney function before routine supply continues. Do not assume the medicines must always be stopped permanently; the immediate decision is to prevent unreviewed exposure while the result is assessed.
Worked example: A patient taking ramipril recently started spironolactone. Their potassium is 5.8 mmol/L against the laboratory’s 3.5 to 5.0 mmol/L range, which is 0.8 mmol/L above its upper limit. Ask about weakness or palpitations, recent illness, supplements, and kidney results. Withhold routine dispensing pending urgent clinical review of the result and treatment plan; escalate immediately if concerning symptoms are present.
Watch the distinction: A combination prescribed intentionally can still become unsafe. A new elevated potassium result needs patient-specific assessment rather than automatic continuation or an unsupported permanent stop.
8. Interpret a glucose pattern
A glucose reading gains meaning from symptoms, meal timing, and the medicine’s mechanism. Sulfonylureas stimulate insulin release, so a missed meal can leave insulin action unmatched by incoming carbohydrate. Sweating, tremor, hunger, or confusion with a low measured glucose supports hypoglycemia. If the patient is awake and able to swallow, provide a readily absorbed carbohydrate according to the care setting’s established treatment approach, then reassess symptoms and glucose and follow with food when appropriate. Inability to swallow, severe confusion, or loss of consciousness requires emergency help and no oral intake. Once the episode is addressed, investigate skipped meals, dose timing, kidney function, and recurrence. Persistent high readings call for a different assessment; treating every abnormal glucose value alike is unsafe.
Worked example: A patient taking a sulfonylurea is sweating after skipping lunch. Their glucose is 3.2 mmol/L. They are alert and can swallow, so provide a readily absorbed carbohydrate and reassess glucose and symptoms under the setting’s treatment approach. Once recovered, help them eat and review the missed meal and dosing pattern with the care team. If they become unable to swallow, seek emergency help.
Watch the distinction: Do not respond to a symptomatic low reading by discussing long-term glucose targets first. Address the immediate episode, then investigate why it occurred.
9. Identify a bleeding signal
Anticoagulants reduce clot formation but can turn an otherwise limited bleed into serious blood loss. Black, tar-like stools may indicate gastrointestinal bleeding; dizziness can suggest reduced circulating volume. Ibuprofen adds gastrointestinal injury risk and can increase bleeding risk when taken with rivaroxaban. Ask about symptom onset, stool appearance, fainting, weakness, other bleeding, and the last doses, without delaying urgent care for a complete history. Direct immediate medical assessment when bleeding is suspected and communicate the anticoagulant, added medicine, and symptoms to the receiving team. A pharmacist should also identify why the anti-inflammatory was started so pain can be managed more safely after the acute problem is addressed. Do not assume a dark stool is harmless without checking context.
Worked example: A patient on rivaroxaban began ibuprofen three days ago and now reports black stools and dizziness. Treat this as possible gastrointestinal bleeding, arrange urgent assessment, and communicate the symptom timeline and both medicines. Ask whether they feel faint and whether someone can help them reach care safely. Record the encounter and follow up on the pain-treatment plan after the bleeding concern is assessed.
Watch the distinction: The ibuprofen may explain added risk, but it does not prove the bleeding source. The immediate task is urgent assessment, not a speculative diagnosis.
10. Separate infection from colonization
A culture identifies organisms in a specimen; it does not by itself show that those organisms cause a symptomatic infection. In urine, bacteria may be present without urinary symptoms. Ask why the sample was collected, whether dysuria, frequency, urgency, fever, flank pain, or systemic illness is present, and whether pregnancy or another specific exception applies. Interpret the result alongside specimen quality and clinical findings. Treating colonization unnecessarily exposes the patient to adverse effects and encourages resistance, while dismissing a genuinely symptomatic infection can delay care. The decision sequence is to establish symptoms and context, identify any exception requiring a different approach, then determine whether antimicrobial treatment or further assessment is warranted. Avoid using the laboratory report as a substitute for a patient assessment.
Worked example: A routine urine culture is positive, but the patient reports no urinary or systemic symptoms. Ask why it was ordered, confirm the absence of symptoms, and check pregnancy and other case-specific reasons treatment might still be considered. If no exception applies, explain that a positive culture alone does not establish symptomatic infection and communicate that assessment to the ordering clinician.
Watch the distinction: “Positive” describes the test result, not the diagnosis. Antibiotics should follow the patient’s clinical situation and applicable exceptions, not the culture result alone.
11. Assess inhaled therapy control
Asthma control is assessed from a pattern, not a single inhaler refill. Ask about daytime symptoms, nighttime waking, activity limits, reliever use, recent flare-ups, and the patient’s own goals. Then check whether the prescribed controller is obtained and used correctly. A reliever usually acts quickly on airway narrowing, while an inhaled corticosteroid reduces airway inflammation over time; the latter may feel less immediately rewarding. Poor technique can make an apparently adequate prescription ineffective. Observe inhaler use, correct errors, and have the patient demonstrate again. Frequent reliever use or persistent symptoms should prompt review of the treatment plan and possible causes, including adherence, triggers, and an incorrect diagnosis. Any severe current breathing difficulty calls for urgent assessment before routine teaching.
Worked example: A patient uses their reliever repeatedly each week but has barely used the prescribed inhaled corticosteroid because “it does nothing right away.” Explain that the controller aims to reduce inflammation and future symptoms, while the reliever acts more quickly. Demonstrate the controller device, ask for a return demonstration, and arrange a control review using symptoms, nighttime waking, and reliever use.
Watch the distinction: A reliever that works promptly can mask poor long-term control. Repeated use is a cue to assess the controller plan and technique.
12. Find the cause of poor blood pressure control
A high home blood pressure pattern may reflect inadequate treatment, inconsistent measurement, missed therapy, or an interfering product. Review several readings with dates and circumstances. Check cuff fit, body position, rest before measurement, and whether the patient repeats readings consistently. Then compare the medicine list with actual use, asking specifically about adverse effects, affordability, and nonprescription products. Ankle swelling can occur with amlodipine and may lead a patient to stop it without telling the team. If so, the readings do not show that the prescribed regimen failed while taken; they show that the current usable regimen needs reassessment. Explore tolerable alternatives with the patient and prescriber, and agree on how readings and symptoms will be followed. Assess urgent symptoms separately.
Worked example: A patient’s recent home readings are higher than their earlier pattern. They reveal that they stopped amlodipine two weeks ago because of ankle swelling. Confirm their cuff and measurement routine, ask whether swelling improved, and update the actual medicine list. Explain that the readings reflect a changed regimen and contact the care team to agree on a tolerable option and follow-up.
Watch the distinction: Escalating treatment solely from high readings can miss the reason they rose. First establish whether the patient is taking the regimen being judged.
13. Assess access as part of therapy
A medicine works only if the patient can obtain, open, measure, and use it. Ask about cost, travel, hand strength, vision, swallowing, language, and the steps required by the dosage form. Match the solution to the barrier: a different container may help limited grip, while a simpler schedule may help workday access. Packaging decisions also involve safety for children or others in the home. Confirm any local requirements before changing a child-resistant closure and explain the trade-off to the patient. Demonstrate the chosen arrangement and ask the patient to use it in front of you. Record the practical barrier and agreed solution so future supplies remain usable. A refill history alone can conceal doses missed because the container could not be opened.
Worked example: A patient says they skip doses when they cannot open the child-resistant bottle. Ask them to demonstrate the difficulty and whether children visit or live in the home. Review packaging options permitted locally, choose one that balances access and household safety, and have the patient open and close it. Update the dispensing instructions so the workable packaging is supplied consistently.
Watch the distinction: Calling this patient “non-adherent” without identifying the container problem misses a solvable cause. Access is part of therapeutic appropriateness.
14. Prioritize competing problems
When several problems appear together, rank them by likely harm and time to harm. Immediate threats to breathing or circulation come before chronic discomfort, cost planning, or routine optimization. Next consider whether an action is reversible, what information is needed, and what matters most to the patient. New facial swelling after an ACE inhibitor raises concern for angioedema, especially if lips, tongue, throat, voice, or breathing are affected. Activate emergency assessment and communicate the suspected medicine. Once the immediate danger is addressed, return to the unaffordable inhaler because lack of access may compromise disease control, then assess the statin symptoms and possible causes. Prioritization does not mean ignoring lower-urgency problems; it creates a sequence with clear follow-up.
Worked example: A patient reports new facial swelling after ramipril, mild muscle discomfort while taking a statin, and an inhaler they cannot afford. Ask immediately about tongue swelling, voice change, and breathing, and arrange emergency assessment for possible angioedema. Communicate ramipril use to the receiving team. Then make a follow-up plan to restore inhaler access and assess the muscle symptoms.
Watch the distinction: Addressing every complaint in the order mentioned can delay care for the most dangerous one. First identify threats that cannot safely wait.
15. Set measurable care goals
A useful care goal names an outcome the patient values and a way to tell whether it changed. Establish the baseline, choose a measurable indicator, set a review period, and agree who will collect the information. For asthma, nighttime waking and reliever use may reveal control better than “feeling better” alone. Include safety measures and treatment burden when relevant. The target should fit the patient’s circumstances and the agreed care plan, not an unsupported universal number. At follow-up, compare the new pattern with baseline, ask whether the patient could use the treatment, and revise the plan if benefit is absent or harms appear. A measurable goal makes a shared decision testable without suggesting that one symptom count captures the whole condition.
Worked example: A patient wants fewer nighttime asthma symptoms. Their diary shows four nights with waking during the previous two weeks. Agree to record nighttime waking and reliever use for the next two weeks while following the verified care plan. At review, compare the new count with four nights, assess daytime function and technique, and decide together whether the plan is helping.
Watch the distinction: “Improve asthma” is too vague to evaluate. A concrete baseline and follow-up measure show whether the patient’s chosen outcome actually changed.
16. Compare therapy benefits and harms
A therapy choice should connect expected benefit to this patient’s risks and ability to use the option. Identify the pain source and severity before comparing treatments. Oral ibuprofen can reduce inflammatory pain, but it can injure the gastrointestinal lining and impair clotting function; recent gastrointestinal bleeding and concurrent anticoagulation make that trade-off especially unfavourable. Consider non-drug measures, a medicine with a safer fit for the pain type, and any relevant contraindications, then discuss the options with the patient and care team. Do not promise that an alternative is risk-free or assume all chronic pain is inflammatory. Agree on what improvement would matter, how long the trial will last, and which adverse effects would require reassessment.
Worked example: A patient taking an anticoagulant asks for oral ibuprofen for chronic knee pain and reports a recent gastrointestinal bleed. Explain that ibuprofen could add bleeding risk and do not recommend routine oral use. Ask about the pain pattern, current treatment, and functional goal. Discuss suitable non-drug and medication options with the care team, then agree on symptom and safety follow-up.
Watch the distinction: A medicine’s usual effectiveness does not make it appropriate for every patient. Recent bleeding and anticoagulation materially change the benefit-harm balance.
17. Plan a safe therapy change
A safe change specifies the medicine, action, timing, responsible person, and monitoring. At transitions, two orders may look valid even when one was meant to replace the other. Compare the prior list, discharge instructions, containers, and actual use; then confirm the intended regimen with an authoritative source. Decide who will correct the active orders and dispensing record, and give the patient one clear list that identifies what to take next. Check whether any doses were already taken under the conflicting instructions and whether symptoms require assessment. Follow-up should test both effectiveness and harm after the change. A plan that says only “clarify with prescriber” leaves the patient and pharmacy team without a usable interim decision.
Worked example: A discharge list contains a new antihypertensive, while the old agent remains active in the pharmacy record and the patient has both bottles. Ask what they took today and check for dizziness. Confirm with the discharging team whether the new agent replaces the old one. Have the responsible team member correct the orders, give the patient the verified list, and arrange blood pressure and symptom follow-up.
Watch the distinction: Removing one entry from the pharmacy computer does not complete the transition. The patient needs clear instructions and the care team needs matching records.
18. Choose an appropriate device
A device is appropriate when it delivers the intended treatment reliably for the person using it. For an inhaler, assess hand strength, coordination, inspiratory ability, vision, understanding, and the exact product. A compatible spacer can reduce the need to coordinate actuation with inhalation for a pressurized metered-dose inhaler, but it is not an attachment for every inhaler type. Show the steps using the patient’s device: prepare it as directed, seal lips around the mouthpiece, actuate at the appropriate point, inhale as instructed, and complete any required device care. Ask for a return demonstration and correct observed errors. If technique remains unreliable, consider a suitable alternative device with the care team. The goal is consistent drug delivery, not simply choosing the easiest-looking product.
Worked example: A patient repeatedly presses their metered-dose inhaler after finishing an inhalation. Confirm the exact inhaler and assess whether a compatible spacer is available. Demonstrate its use, then ask the patient to assemble it and show one full inhalation sequence. If coordination improves, record the device choice and technique taught; if it does not, discuss another suitable delivery option.
Watch the distinction: A spacer is not a universal fix for every inhaler. Confirm device compatibility and observe the patient using it before concluding treatment delivery has improved.
19. Explain the rationale for a plan
Patients are more likely to follow a plan they can explain in their own words. Connect the instruction to the underlying reason without making claims the evidence cannot support. With an antibiotic, feeling better can mean symptoms have eased before the agreed treatment course is complete; it does not independently establish that treatment can stop. Confirm the diagnosed infection, exact prescribed directions and duration, adverse effects, missed doses, and any reason the plan may need review. Explain what to do if symptoms worsen or a serious reaction occurs. Avoid suggesting that every infection requires the same course length or that completing a course guarantees success. Use teach-back: ask the patient to describe the schedule and what would prompt contact.
Worked example: A patient taking an antibiotic says symptoms improved and asks to stop early. Check the bottle and order to confirm the prescribed course, ask about missed doses and adverse effects, and explain why symptom relief alone does not change the agreed duration. Tell them to follow the verified plan unless the treating clinician changes it, and identify worsening symptoms or a serious reaction as reasons for prompt reassessment.
Watch the distinction: “Always finish antibiotics” is too blunt when the diagnosis, order, or adverse effects need review. Explain and verify this patient’s actual treatment plan.
20. Respond to an administration reaction
Rapid symptoms affecting more than one body system after medication administration can indicate anaphylaxis. Wheeze suggests airway involvement, widespread hives show a skin reaction, and light-headedness may reflect impaired circulation. Stop the administration, call for emergency help, and use the setting’s authorized anaphylaxis protocol immediately; intramuscular epinephrine is the key emergency medicine when indicated by that protocol. Position and monitor the patient according to their breathing and circulation, and do not leave them alone. Record the medicine, route, time, symptoms, treatment, and response for the receiving team. Improvement after initial treatment does not remove the need for emergency assessment and observation. Confirming the exact trigger and updating the allergy record follows stabilization, not the other way around.
Worked example: Minutes after an injection, a patient develops wheeze, widespread hives, and light-headedness. Stop the injection process, recognize possible anaphylaxis, summon emergency services, and give immediate treatment under the site’s authorized protocol. Monitor breathing and circulation while help arrives. Tell the receiving team the injected product, time of administration, symptom sequence, treatment given, and response; document the event afterward.
Watch the distinction: Waiting to see whether the hives fade can delay treatment of airway or circulatory compromise. Treat the systemic pattern as an emergency.
21. Teach practical medication use
Start counseling by asking what the patient understands about the medicine and watching how they use the device. An inhaled corticosteroid reduces airway inflammation over time; it does not provide the immediate relief expected from a reliever inhaler. Explain which inhaler serves each purpose, using the patient's actual treatment plan. Demonstrate preparation, inhalation and any device-specific steps, then ask the patient to show you. Technique matters because medicine left in the device or deposited mainly in the mouth cannot work as intended in the lungs. Rinsing and spitting after use reduces local effects such as oral thrush. Discuss what improvement the patient should track, how regularly to use the controller as prescribed, and what worsening symptoms require prompt assessment. Tailor the explanation to the patient's device, abilities and concerns.
Worked example: A patient says their new inhaled corticosteroid did nothing during yesterday's breathing episode. I explain that it is the regular preventive inhaler and confirm which prescribed inhaler is their reliever. I demonstrate their device and ask them to repeat the steps, then explain rinsing and spitting afterward. We review their worsening-breathing instructions and arrange a control review because they needed acute relief.
Watch the distinction: Calling the controller ineffective after one episode confuses prevention with immediate relief. Check technique and regular use, while assessing the episode and reliever needs separately.
22. Support a change in substance use
Ask permission to discuss tobacco use, then learn what the patient uses, when, and what it does for them. Smoking may provide a familiar response to stress even when the patient wants to change, so a lecture about harm alone rarely solves the practical problem. Ask about previous attempts, withdrawal symptoms, household exposure and the patient's preferred goal. A patient ready to cut down can choose a measurable first step, identify a predictable trigger and rehearse another response to it. Behavioral support and suitable cessation medicines can reduce withdrawal and improve the chance of sustained change; assess medical history, preferences and access before recommending a product. Agree on follow-up that checks both progress and difficulty. A return to smoking gives information about triggers and support needs, rather than proof that change is impossible.
Worked example: A patient smokes after work to manage stress and wants to cut down. They identify the drive home as the strongest trigger and choose to make that drive smoke-free on weekdays, keeping gum and a short walk available afterward. I ask about previous withdrawal and discuss behavioral support and cessation medicine options. At follow-up, we will review which drives were smoke-free and what interfered.
Watch the distinction: Assuming every smoker is ready to quit immediately can end the conversation. A specific reduction goal can build engagement while leaving room to discuss complete cessation.
23. Follow effectiveness and safety
A useful follow-up asks three different questions: did the treatment help, did it cause harm, and was it taken as intended? For a diuretic, changes in swelling, breathing or weight may show benefit. Standing dizziness, falls, thirst and changes in blood pressure or relevant laboratory results may signal excess fluid loss or another adverse effect. Establish when symptoms began relative to the medicine, whether the patient changed other drugs, and how consistently doses were taken. Compare measurements with the patient's baseline and assess hydration, rather than interpreting one reading alone. New fainting or severe symptoms need urgent assessment. If benefit is clear but dizziness appears, coordinate a timely review of dose, fluid status and other blood pressure medicines. Document the decision and a date for reassessment so an unresolved safety problem does not become routine.
Worked example: One week after starting a diuretic, a patient's ankle swelling is visibly better, but they feel light-headed when rising. I ask when dizziness began, check seated and standing blood pressure if feasible, review fluid intake and other medicines, and assess for falls or fainting. I arrange prompt therapy review and tell the patient to seek urgent help for fainting or severe weakness.
Watch the distinction: Improved edema does not prove the regimen is safe. Dizziness may reflect excessive fluid loss, low blood pressure or another cause that needs a focused assessment.
24. Investigate apparent non-adherence
A refill record shows medicine was supplied, not that it was swallowed or tolerated. Ask the patient to describe a usual day of dosing without implying blame. Compare their account with the prescribed directions and explore reasons for any difference: an intentional choice, misunderstanding, cost, difficulty swallowing, a disrupted routine or adverse effects. These causes lead to different solutions. For metformin-associated diarrhea, establish the formulation, timing with meals, symptom severity, onset after dose changes and any dehydration or other concerning symptoms. Taking a smaller amount may ease symptoms but can also reduce glucose control. Discuss practical measures that fit the prescribed product and coordinate a tolerable regimen with the authorized prescriber where a change is needed. Record the amount actually taken, the reason, the agreed action and how glucose control and tolerability will be reassessed.
Worked example: A patient refills metformin on time but says they take half the prescribed amount because each full dose causes diarrhea. I record their actual use, ask about formulation, meals and symptom severity, and check for dehydration. I explain why the refill history was misleading, discuss tolerability measures appropriate to their product, and contact the prescriber about a revised regimen with follow-up for symptoms and glucose.
Watch the distinction: Labelling this patient forgetful misses the reason for reduced use. More reminders will not solve persistent diarrhea and may make the patient less willing to disclose it.
Providing Care: Distribution
25. Screen the prescription
Screen an order before entering it as a dispensing instruction. Match the patient and prescriber, assess whether the order is authentic and permitted in the applicable jurisdiction, and check the medicine, formulation, strength, route, frequency, duration and quantity for clarity. Then consider indication, allergies, current therapy, interactions and whether the patient can use the product. A prior fill can supply context but cannot resolve a missing field on a new order: the intended treatment may have changed. Separate a clerical uncertainty from a clinical concern, and direct each to someone able to resolve it. Clarification should produce an unambiguous, traceable instruction before preparation proceeds. The NAPRA pharmacist competencies include both prescription completeness and therapeutic appropriateness, so checking that words are legible is only part of the pharmacist's decision.
Worked example: An order for a patient says, “Take one tablet daily,” but the medicine is available in two strengths. Last month's fill shows the lower strength; the current order does not specify either one. I hold processing, confirm the intended strength and directions with the authorized prescriber, update the order record, then assess the confirmed regimen before preparing a labelled supply.
Watch the distinction: Copying the last strength turns a historical clue into an unauthorized assumption. The patient may have had a dose change, so the current order needs clarification.
26. Calculate a liquid quantity
Liquid calculations begin with the prescribed dose and the concentration printed on the specific product. Write both as quantities with units, then arrange the ratio so milligrams cancel and millilitres remain: required volume equals prescribed mass multiplied by labelled volume divided by labelled mass. Check whether the concentration refers to the active ingredient, a salt or a reconstituted product, since apparently similar labels can express different things. Keep intermediate figures unrounded and round only to a volume the supplied measuring device can reliably deliver. Verify the dosing frequency and calculate the total volume separately if the order requires it. A correct number is still unsafe if the label omits units or the patient receives an unsuitable household spoon. The PEBC Pharmacist OSCE practice questions can be used to rehearse saying the calculation and checking the finished label aloud.
Worked example: A hypothetical order specifies 250 mg per dose. The selected suspension contains 125 mg per 5 mL. Required volume is 250 mg × 5 mL ÷ 125 mg = 10 mL per dose; the mg units cancel. I check that the bottle is the stated concentration, label 10 mL at the prescribed frequency, and supply a device marked to measure 10 mL.
Watch the distinction: Reading 125 mg as the amount per millilitre would give a fivefold error. Retain the full label ratio, 125 mg per 5 mL, throughout the calculation.
27. Prepare and label for safe use
Preparation starts with product identity, required amount and a method that preserves quality. Confirm whether a suitable commercial formulation exists before proposing a compounded one. For a preparation, distinguish ordinary nonsterile work from a situation involving sterility or a hazardous ingredient; those hazards demand equipment, training and controls appropriate to the work. A hazardous powder can expose staff during measuring and dispersal and can contaminate the workspace or other preparations. Do not assume that making a liquid is a simple substitution for a tablet. Once an appropriate product or preparation is available, choose packaging that protects it and lets the patient use it safely. The label should express the verified dose in practical units, route, frequency and any product-specific handling instructions. Check that the patient can measure or administer the dose and understands any storage directions supported for that exact product.
Worked example: A patient needs an oral liquid, no suitable commercial form is available, and the proposed ingredient is hazardous. I identify exposure during powder handling as the immediate preparation risk and do not compound it in an unequipped dispensary. I arrange supply through a service equipped and authorized for that ingredient, then verify its concentration, packaging and patient-specific label before release.
Watch the distinction: A liquid's route of administration does not make its preparation low risk. Hazardous ingredients require exposure controls even when the finished medicine will be taken by mouth.
28. Verify the finished product
The final product check compares what has actually been prepared with the verified order and dispensing record. Read the manufacturer label and inspect the medicine rather than relying on the printed pharmacy label alone. Confirm patient, drug, strength, dosage form, release characteristics, quantity, directions and expiry or other quality concerns. Modified-release and immediate-release products may contain the same active ingredient yet deliver it differently, so an apparent name match cannot establish equivalence. Inspect packaging integrity and the physical product where possible. If a discrepancy is found, stop release, replace or correct the product, and repeat the check from the source order. Also ensure the pharmacist's therapeutic assessment and any required counseling are complete. A technical double check helps interrupt selection errors, but it does not substitute for judging whether the medicine is appropriate for this patient.
Worked example: The verified order specifies extended-release metoprolol. The prepared bottle contains immediate-release metoprolol tablets, although the patient name, ingredient and strength match. I stop release, isolate the incorrect supply, select the ordered formulation and repeat the product and label checks. I confirm the therapeutic review and explain the correct product to the patient before handing it over.
Watch the distinction: Matching ingredient and milligrams is insufficient when release characteristics differ. The two formulations can produce different concentration patterns and may have different dosing instructions.
29. Release and manage supply safely
Release is the last safety decision, not merely handing over a completed package. Confirm that therapeutic and technical checks, any needed consultation and patient identification are complete. Inventory quality also matters: a product that experienced uncertain storage conditions cannot be judged safe by appearance alone. For temperature-sensitive stock, isolate affected units, reconstruct available time and temperature evidence, and seek a disposition based on information applicable to the exact product. Keep suspect units unavailable for selection while arranging suitable replacement stock or another clinically appropriate supply plan. Communicate a delay plainly to the patient, especially when interruption could harm them, and coordinate continuity of therapy. Track the affected lot, the evidence reviewed and the disposition. A shortage similarly requires checking whether an alternative matches the patient's therapy and whether the order needs authorization before substitution.
Worked example: A refrigerated shipment arrives warm, and its temperature record has a gap. I quarantine the affected lot and document the observed condition and missing period. I obtain product-specific stability advice before deciding whether it can be used, while arranging verified stock for a patient due to start treatment. At release, I confirm the patient's identity, completed checks and counseling.
Watch the distinction: A package that looks intact may still have lost potency after improper storage. An incomplete temperature history needs an evidence-based disposition before the product is supplied.
Knowledge and Expertise
30. Frame an evidence question
A focused evidence question keeps a search tied to a decision. Identify the patient group, the proposed intervention, the realistic comparator and outcomes that matter. These elements are often called PICO. Define the patient's circumstances closely enough to judge applicability: age, other medicines, functional concerns and treatment goals may all change the balance. For a sleep aid, falling asleep sooner is one outcome; next-day alertness, falls, confusion and anticholinergic effects may matter more to an older adult. Decide whether the comparison is no drug, behavioral measures or another medicine, and look for evidence that actually makes that comparison. A clear question also reveals missing clinical information before recommending anything. Evidence appraisal and clinical judgment then connect the research result with what the patient can use and values. Related reading in the Part I study guide can reinforce how to interpret comparative evidence.
Worked example: An older adult asks whether a sedating antihistamine will help them sleep, but they already report morning unsteadiness. I frame the question as: in older adults with insomnia, does this antihistamine, compared with non-drug sleep measures, improve meaningful sleep while avoiding next-day impairment and anticholinergic harm? I assess their medicines and unsteadiness before considering a recommendation.
Watch the distinction: Searching only for faster sleep onset leaves out harm that may dominate the decision. Define patient-important benefit and safety outcomes before reading a product claim.
31. Judge evidence quality
An outcome can sound persuasive while offering little evidence of a treatment effect. An uncontrolled survey cannot show what would have happened without the product, and people who respond may differ from those who do not. Satisfaction is also vulnerable to expectations and may not match changes in symptoms or functioning. Prefer a study with a relevant comparison group, clear patient selection, similar care apart from the intervention, sufficient follow-up and outcomes important to the patient. Random assignment can reduce systematic differences between groups, although study conduct, missing data and selective outcome reporting still matter. Look at effect size and harms, not merely whether a result is described as significant. Then ask whether the participants resemble the patient in front of you. A small, poorly controlled finding may justify further investigation, but it should not carry the same weight as a credible comparative result.
Worked example: A sleep product advertises that eight of ten surveyed users were satisfied. I explain that the ten-person survey has no comparison group, so the result cannot separate product benefit from expectations or natural variation. I seek comparative evidence on sleep quality and next-day effects, then discuss those outcomes alongside the patient's symptoms and other medicines.
Watch the distinction: Eight satisfied users are not an 80% treatment success rate. Without a comparator and a defined clinical outcome, that fraction cannot estimate the product's added benefit.
32. Apply absolute risk
Relative effects need a baseline risk to become meaningful for a patient. First calculate the risk in each group using the same outcome and follow-up period. Subtract treated risk from untreated risk to get absolute risk reduction when treatment helps. Dividing that reduction by untreated risk gives relative risk reduction. If useful, the reciprocal of the absolute reduction as a decimal gives a number needed to treat, rounded up to a whole person; it describes a group over the stated period, not an individual guarantee. Check whether the trial population and baseline risk resemble the patient. If baseline risk is lower, the same relative reduction usually yields a smaller absolute benefit. Discuss adverse effects with their own absolute frequencies when available. Avoid comparing a relative benefit with an absolute harm because the different scales make the trade-off misleading.
Worked example: In a hypothetical study over one year, 10 of 100 untreated patients have an event, versus 6 of 100 treated patients. Risks are 10% and 6%; absolute reduction is 10% − 6% = 4 percentage points, or four fewer events per 100. Relative reduction is 4% ÷ 10% = 40%. The number needed to treat is 1 ÷ 0.04 = 25 for one year.
Watch the distinction: A 40% relative reduction does not mean 40 of 100 patients benefit. Here the observed difference is four events per 100 over the study period.
33. Combine evidence with preference
Evidence informs an option's expected effects, while clinical judgment tests whether those effects are relevant and achievable for this patient. Compare indication, likely benefit, adverse effects, administration, cost and access. Two formulations with similar efficacy in studies can differ substantially in usefulness when one cannot be swallowed or paid for. Ask which outcomes the patient values and what barriers they foresee, then explain the trade-offs in plain terms. Confirm that the preferred formulation is appropriate for the prescribed medicine; tablets cannot always be split or crushed, and a change in release characteristics can alter exposure. Where an authorized order must change, present the care team with a specific alternative and the reason. Agree on what will show that the chosen treatment works and remains tolerable. Preference is part of the evidence-informed decision because a treatment that cannot be used as intended offers little practical benefit.
Worked example: Two prescribed formulations have similar expected efficacy. The patient cannot swallow the larger tablet and says its cost would cause missed doses. I confirm that the smaller, affordable formulation delivers the intended regimen and recommend it to the care team for authorization. I explain to the patient how to use the selected product and arrange follow-up for benefit and tolerability.
Watch the distinction: Choosing the statistically similar but unusable tablet ignores whether treatment can be taken. Practical feasibility and patient preference can determine which clinically suitable option succeeds.
Communication and Collaboration
34. Open a focused conversation
A focused opening invites the patient's concern before the pharmacist supplies an explanation. Begin with an open question such as “What worries you most about starting it?” and allow enough silence for an answer. Reflect the specific concern back in ordinary words, then check that you understood it. This distinguishes fear of dependence from fear of an allergic reaction, cost or a prior bad experience; each requires different information. Ask what the patient already knows and what decision they are trying to make. Give accurate, medicine-specific counseling rather than reassuring them that every concern is unfounded. If the medicine can cause dependence, describe that risk and the intended use honestly. End by asking what questions remain and checking the patient's understanding. The sequence lets the patient participate in the decision and prevents a polished but irrelevant explanation.
Worked example: A patient says, “This medicine scares me.” I ask what feels frightening and they say a relative became dependent on a different medicine. I reflect, “You're worried this treatment could lead to the same problem.” I confirm the actual medicine and intended duration, explain its relevant dependence risk and alternatives accurately, and ask what information would help them decide.
Watch the distinction: Immediately listing adverse effects may miss the patient's real fear. Establish what “scares me” means before choosing which facts, options and safeguards to discuss.
35. Explain without jargon
Plain language should preserve the causal idea and the action the patient needs to take. Translate “natriuresis” into “your kidneys pass more salt and water into urine,” then connect that effect to the patient's goal, such as less swelling. Avoid promising that every symptom will improve or implying that more urination alone proves treatment is optimal. Explain when to take the medicine according to the confirmed order, what changes to observe and what problems merit contact. For a diuretic, changes in weight or swelling may help track benefit, while dizziness or weakness can suggest a safety problem. Ask how the patient would describe the medicine to someone at home; their answer shows whether your wording worked. Use numbers only when they relate to the patient's actual plan, and distinguish routine monitoring from symptoms needing prompt assessment.
Worked example: A patient asks what their diuretic does. I say, “It helps your kidneys remove extra salt and water, which may reduce your swelling.” We agree to watch their swelling and record weights as directed in their care plan. I ask them to report new standing dizziness or marked weakness promptly, then ask them to explain the medicine's purpose in their own words.
Watch the distinction: Replacing jargon with “water pill” alone leaves out why it helps and what could go wrong. Link the kidney effect to both benefit and safety.
36. Confirm understanding
Teach-back tests the explanation rather than the patient. After giving the confirmed instructions in manageable parts, ask how the patient will take the medicine when they get home. Listen for timing, dose and practical barriers. If their account differs from the order, correct the explanation without blame, then ask again. “Twice daily” describes two separate dosing times; taking both doses together changes the intended pattern of drug exposure and may increase adverse effects. Use the exact schedule on the patient's prescription and clarify any food or spacing instructions relevant to that product. A written label or calendar can support memory, but it cannot replace checking understanding. If a patient still cannot follow the plan because of work, sleep or caregiving routines, collaborate on an authorized, feasible alternative rather than accepting an unsafe interpretation.
Worked example: The confirmed antibiotic order says one dose twice daily. The patient says they will take both doses each morning. I respond, “I may not have explained the timing clearly: it is one dose in the morning and one later in the day, following this label.” We choose times that fit their routine, then I ask them to describe tomorrow's two doses.
Watch the distinction: Asking “Do you understand?” often elicits yes without showing what the patient will do. Have them describe the actual dosing plan and correct any mismatch.
37. Write an actionable message
A message to another professional should make the requested decision easy to identify. State the patient, the immediate concern, the facts that support it and what response is needed by when. Include the current medicines, relevant dates, symptoms and monitoring results, while distinguishing confirmed facts from information still being checked. Trimethoprim-sulfamethoxazole can increase warfarin's anticoagulant effect, creating bleeding risk; the message should therefore ask for an alternative antimicrobial when clinically suitable or an explicit anticoagulation and monitoring plan. Assess whether the patient already has bleeding symptoms that change urgency. Communicate directly when a delayed reply could expose the patient to harm, then record the agreed plan and tell the patient what to do. Written communication can be rehearsed using the PEBC OSCE station formats as examples of task types.
Worked example: I message the prescriber: “This patient takes warfarin and was prescribed trimethoprim-sulfamethoxazole today. The combination may raise anticoagulant effect and bleeding risk. I am checking for bleeding and the latest INR. Please advise promptly whether an appropriate alternative is available or provide a specific warfarin and INR monitoring plan before treatment starts.” I document the response and counsel the patient on the confirmed plan.
Watch the distinction: Writing only “interaction found” leaves the recipient to reconstruct the risk and decision. Include the medicines, likely harm, relevant patient facts, urgency and requested action.
38. Handle disagreement constructively
Disagreement is easiest to resolve when both parties can see the clinical facts and the immediate decision. State the documented reaction, its timing and features, and whether the proposed order involves the same drug or a plausible cross-reacting medicine. A severe reaction label deserves urgent clarification before supply, but an unclear record should be investigated rather than treated as certain anaphylaxis. Acknowledge the prescriber's treatment urgency and offer a practical route: check the reaction history, consider an effective alternative, or obtain specialist advice when needed. Avoid attributing motives or arguing from authority. If risk remains unresolved, explain why dispensing is paused and how the patient will receive timely care. Record the evidence, contacts and agreed plan. The goal is a safe treatment decision that addresses the underlying illness and the reported reaction.
Worked example: A prescriber asks for immediate dispensing of a drug the patient says caused throat swelling and wheezing shortly after a prior dose. I relay those features and the matching drug name, explain the risk of a serious repeat reaction, and ask about an effective alternative for the current infection. I hold that supply while we agree on an authorized, timely treatment plan and tell the patient what was decided.
Watch the distinction: Either dispensing to avoid conflict or simply saying “allergy” without details weakens safety. Describe the reaction and work toward a usable treatment decision.
39. Communicate through an interpreter
A complex medicine change requires the patient's own informed understanding. Ask which language they prefer for health discussions and arrange a qualified interpreter through an appropriate channel. Speak to the patient directly in short, complete statements, pausing for interpretation and allowing questions. A family member may provide support if the patient wants, but may omit details, answer for the patient or make a private topic harder to discuss. For an anticoagulant change, show the old and new medicine names, identify exactly which regimen is current, and explain bleeding signs and the follow-up plan from the confirmed order. Use teach-back through the interpreter: ask the patient to describe what they will take and what they will stop. Document the language support used and any remaining uncertainty. Never treat a polite nod as evidence that the patient understands a high-risk transition.
Worked example: A patient's relative offers to translate a change from warfarin to another anticoagulant, but the patient appears uncertain. I ask the patient's language preference and arrange a qualified interpreter. Using the verified transition plan, I speak directly to the patient, identify the medicine to stop and the one to use, and have them explain the plan back through the interpreter.
Watch the distinction: A willing relative does not establish accurate interpretation or patient consent. For a complex anticoagulant change, use qualified language support and verify the patient's own understanding.
40. Support an autonomous choice
An informed choice requires more than offering a recommendation. Ask what happened with the previous medicine, including the reaction, its severity, timing and effect on daily life. Explain the expected benefit of the proposed treatment in terms the patient values, along with material risks and reasonable alternatives. Discuss whether a different formulation, medicine or monitoring plan could address the concern, without minimizing the prior experience. Check understanding and ask what matters most in the decision. If the patient declines after understanding the options, respect that choice and agree on a safe next step, including symptom monitoring and how to revisit the decision. Document the patient's reason, information discussed and plan. Urgent threats to health still require clear advice about prompt assessment, but they do not justify coercive language or a false claim that the patient has no choice.
Worked example: A patient declines a recommended medicine because a previous dose caused disabling nausea. I clarify which drug caused it and how soon symptoms appeared, explain the proposed medicine's likely benefit and relevant adverse effects, and discuss suitable alternatives with the care team. The patient still declines today. I record their choice, agree on monitoring and arrange a review if their goals or symptoms change.
Watch the distinction: Calling refusal “non-adherence” skips the patient's reasons and autonomy. Explore the experience, explain options clearly and plan continued care even when the recommendation is declined.
41. Agree on a feasible plan
A plan works only if the patient can follow it. Ask when doses are missed, what happens during a typical workday, and whether cost, storage, privacy or side effects make the prescribed schedule difficult. Then check which changes are clinically suitable: moving a dose may depend on food, interactions or the intended dosing interval; switching formulation may change how the medicine is absorbed or how often it is taken. Agree on an option with the patient and obtain an authorized order when the regimen must change. Name who will contact the prescriber, when the patient will start the confirmed schedule, and how success will be checked. The PEBC pharmacist qualifying exam guide provides broader context for practising these patient conversations.
Worked example: A patient takes a prescribed medicine at breakfast and midday but misses the midday dose at work. The pharmacist asks about lunch breaks, food instructions and cost. After confirming that an available alternative formulation suits the condition, the pharmacist asks the prescriber to authorize it and confirms coverage. The patient chooses an evening routine, repeats the approved directions, and agrees to review missed doses at follow-up.
Watch the distinction: Telling the patient to set a phone alarm assumes forgetfulness is the problem. If taking medicine at work is impractical, an alarm leaves the barrier in place.
42. Maintain trust during a refusal
A refusal can preserve trust when you explain the exact safety problem and take responsibility for resolving it. First establish what the patient needs now, including their last dose and the consequence of interruption. Compare the request with the active order, dispensing history and any recent change. If two directions conflict, say which detail remains uncertain; avoid implying that the patient caused the problem. Contact a source able to confirm the current order and give the patient a realistic update. Once clarified, check therapeutic suitability and communicate the verified instructions. If treatment may be interrupted before clarification, assess the clinical risk and arrange a lawful continuity option available in that jurisdiction. Record the discrepancy, contacts, decision and information given to the patient.
Worked example: A patient requests more tablets today. The pharmacy record shows one tablet daily, while a recent discharge sheet says two; the prescriber’s current order is unclear. The pharmacist explains the conflicting directions, asks when the next dose is due and contacts the discharge team promptly. After receiving a confirmed order, the pharmacist checks the regimen, supplies it if appropriate, and gives the patient clear directions.
Watch the distinction: A bare statement that the refill is refused sounds arbitrary and leaves the treatment gap unresolved. Explain the conflict and actively pursue a safe, authorized plan.
43. Communicate a therapy problem to a prescriber
A useful consultation gives the prescriber a decision they can act on. Identify the suspected medicine, start date, symptom timing, severity, adherence and other plausible causes. An angiotensin-converting enzyme inhibitor can cause a persistent dry cough through accumulation of bradykinin and related mediators. That mechanism makes a cough after initiation plausible, but it does not prove causation. Ask about fever, breathlessness, chest pain and facial swelling; swelling or breathing difficulty requires urgent assessment. State the patient's treatment indication, blood pressure course and preference, then suggest an alternative for consideration if clinically suitable. Agree on who changes the order and how symptoms and blood pressure will be reviewed. The NAPRA pharmacist competencies support this collaborative decision-making role.
Worked example: A patient reports a dry cough that began after starting ramipril and has persisted for weeks. They report no fever, breathlessness, chest pain or swelling. The pharmacist tells the prescriber the timing, current blood pressure information and impact on sleep, and suggests considering an angiotensin receptor blocker if appropriate. The pharmacist requests a confirmed change, then plans to reassess cough resolution and blood pressure.
Watch the distinction: Calling every cough an ACE inhibitor reaction may miss infection or another cause. Report the supporting timing and relevant negatives while making the suspected link clear.
44. Coordinate within the pharmacy team
An early refill is a signal to investigate, not a diagnosis of misuse. The team member who notices it should pass along the drug, directions, last fill date, quantity and patient explanation without making an unsupported clinical judgment. The pharmacist compares the prescribed regimen with actual use, checks for authorized dose changes, lost supply, administration errors and worsening disease, and assesses immediate safety. The decision may require an updated order, counseling, a clinical review or a lawful supply arrangement. Communicate the resulting plan to the team so processing, therapeutic assessment, technical verification and patient instructions agree. A closed-loop handoff includes the specific action and confirmation that it was received. Document the reason for the early request and the final decision.
Worked example: A technician flags an early inhaler refill and reports that the patient says it is empty. The pharmacist asks about technique, doses used and worsening breathing. The patient describes frequent extra reliever use and nighttime symptoms. The pharmacist assesses control, arranges timely review of treatment and gives urgent-care advice for severe breathing trouble. The technician receives the confirmed dispensing instructions after that assessment.
Watch the distinction: Automatically declining an early refill treats the date as the whole story. Increased use can reveal poor disease control, a dose change or a supply problem.
45. Hand over care at a transition
A transition creates risk because the old and new regimens may both appear active. Build a current list from discharge orders, the pre-admission history and what the patient has actually been told to take. Mark each medicine as continued, changed, started or stopped. For insulin, specify the product, concentration, delivery device, dose units, timing and glucose monitoring plan; a brand or vague instruction alone is insufficient. Resolve any conflicting dose before the next administration rather than passing uncertainty to the patient. Send the verified list and unresolved questions to the receiving pharmacist and prescriber through an appropriate channel, with a named person responsible for closing each issue. Ask the patient to explain which supplies they will use and whom they will contact about abnormal readings.
Worked example: Discharge paperwork lists a new insulin pen but gives two different evening doses. The patient still has a home vial. The pharmacist confirms the intended dose with the discharge team before the next injection, explains that the old vial is no longer part of the verified plan, and checks pen use. The receiving pharmacy gets the confirmed list, glucose monitoring instructions and contact for follow-up.
Watch the distinction: Sending both lists without highlighting the conflict merely transfers the error risk. The receiving team and patient need one verified regimen and an owner for remaining questions.
46. Make a formal referral
A formal referral connects a specific finding to the service able to assess it. First decide how quickly the patient needs care by considering progression, infection signs, circulation, sensation and systemic illness. A new foot wound with worsening numbness may go unnoticed or deteriorate, particularly when protective sensation is reduced. Provide immediate practical advice within pharmacy competence, such as protecting the wound from further pressure, while arranging appropriate clinical assessment. Tell the receiving clinician what was observed, when it began, relevant conditions and medicines, and any urgent concerns. Confirm where and when the patient will be seen and what to do if the condition worsens before then. Record the referral and close the loop when feasible.
Worked example: A patient with diabetes reports progressive foot numbness and a newly discovered wound. The pharmacist asks about fever, spreading redness, drainage and ability to walk, and advises against putting pressure on the area. The pharmacist arranges prompt assessment with an appropriate foot-care or medical service, sends the findings and medication list, and tells the patient where to go and which worsening signs require urgent help.
Watch the distinction: Giving only a generic referral leaves the next clinician without the findings needed to triage care. The patient also needs a clear destination and timing.
47. Respond to a referral request
When another professional requests medication advice, clarify the exact product and the practical problem before answering. Modified-release design controls how quickly drug is delivered; crushing can destroy that control and cause an unintended release pattern. Check the product's specific formulation because tablets bearing the same drug name may differ. If crushing is unsuitable, identify a usable alternative, such as an immediate-release formulation with a revised schedule, but do not assume dose-for-dose interchangeability. The authorized prescriber should confirm the new regimen, and the care team needs directions that match the patient's swallowing or feeding needs. State what can be done now, what requires authorization and what should be monitored after a change.
Worked example: A nurse asks whether an extended-release metoprolol tablet can be crushed for a patient who cannot swallow it. The pharmacist verifies the exact product and advises against crushing that modified-release tablet. The pharmacist identifies an available immediate-release formulation for the prescriber to consider, explains that its schedule must be specified in a new order, and asks the nurse to use only the confirmed directions.
Watch the distinction: Assuming all metoprolol tablets can be prepared alike ignores the release formulation. A different dosage form may require a different schedule and an authorized order.
48. Transfer a prescription safely
A prescription transfer is also a handoff of clinical context. Confirm the patient's identity and chosen receiving pharmacy, then establish the current authorized drug, strength, formulation, directions and remaining supply under the rules of the applicable province or territory. Reconcile recent changes against the patient's account and records before sending them. A transfer that reproduces an obsolete direction can cause duplication or under-treatment even when the administrative details are complete. Tell the receiving pharmacist about unresolved questions, monitoring needs and any action already taken; confirm receipt where the process requires it. Explain to the patient which pharmacy will supply the next fill and which directions are current. Further OSCE practice questions can help rehearse this concise handoff.
Worked example: A patient moves pharmacies after a prescriber changes their tablet strength. The old label remains in the dispensing record, while the new authorized order is documented separately. The pharmacist verifies the new order and patient use, transfers the current details under applicable rules, and alerts the receiving pharmacist to the discontinued strength. The patient is told which bottle and directions now apply.
Watch the distinction: Copying the last dispensed label as the active prescription can revive a superseded dose. Verify changes and explicitly identify what has been discontinued.
49. Document a clinical decision
A clinical note should let the next pharmacist reconstruct the reasoning and continue care. Record the concern, the patient's account, other information sources and any facts still uncertain. Separate observations from interpretation: two anticoagulants on a list are a discrepancy until the intended regimen is verified. Then document the clinical risk, who was contacted, the confirmed decision, patient preference and exact instructions given. Include the follow-up owner and time or trigger, such as review after the next laboratory result. Use dates, medicine names, strengths and directions where relevant; vague phrases such as “patient advised” do not show what was advised. A recognized structure can help, but clarity and traceability matter more than the label placed on the note.
Worked example: The patient says they take warfarin, while a discharge list starts apixaban. The pharmacist records both sources, last known doses and bleeding symptoms asked about. After contacting the discharge prescriber, the pharmacist documents the confirmed transition plan, repeats it to the patient, identifies which supply should no longer be used and records who will follow up. The note identifies when and how that confirmation occurred.
Watch the distinction: Writing “duplicate anticoagulants resolved” hides the evidence and instructions. Another clinician must be able to see which regimen was confirmed and what the patient was told.
50. Maintain a secure, accurate record
A trustworthy record preserves what happened, including corrections. If information is placed in the wrong patient's chart, stop further use of that entry and follow the system's correction function so the original and correction remain traceable. Identify whether anyone viewed or acted on the misplaced information and escalate the privacy concern through the appropriate channel. Place the clinical information in the correct chart only after verifying the patient's identifiers. Share the minimum information needed with people authorized for the purpose; secure messaging and recipient checks matter because even an accurate note can cause harm when sent to the wrong person. Do not silently overwrite an entry or copy unrelated details into another record. Document the correction and any clinical actions needed because of the error.
Worked example: A pharmacist notices that counseling about an anticoagulant was entered in another patient's chart. They verify both identities, flag the misplaced note using the record system's correction process and notify the privacy lead. They check whether the wrong entry affected care, then enter the counseling in the correct chart through an authorized workflow. The correction remains linked to the original entry.
Watch the distinction: Deleting or replacing the wrong note without a trace makes later review unreliable. The record should show what was entered, how it was corrected and any resulting action.
Leadership and Stewardship
51. Address a community health barrier
Access barriers alter the effectiveness of treatment just as surely as a poorly chosen drug. Ask which step fails: travel, appointment booking, internet access, cost, language or time away from work. Then identify a service the patient can actually reach, confirm eligibility and contact method, and help make the connection with consent. Consider whether pharmacy follow-up can be timed with medicine pickup, completed by telephone or coordinated with a local care provider. Avoid assuming that a digital option is accessible merely because it exists. The plan should name the service, the next action, who will make contact and a fallback if the patient cannot connect. Follow-up tests whether care was obtained, rather than treating a referral as completion.
Worked example: A patient misses repeated appointments because the clinic is far away and they have no reliable internet. The pharmacist asks whether telephone contact and a nearby community service are workable. With permission, the pharmacist helps arrange a phone appointment with a reachable service and coordinates pharmacy follow-up for the patient's usual pickup day. The patient receives the phone number and knows whom to call if the appointment fails.
Watch the distinction: Handing the patient a website address does not solve limited internet access. Match the route to care to the barrier the patient actually describes.
52. Protect health during disruption
During a disruption, protect people, product quality and continuity of essential treatment in that order. An outage may affect lighting, electronic records, refrigeration, communication and the ability to verify orders. Secure the area, account for patients who need urgent medicines, and establish a safe way to access reliable records or coordinate with another service. For refrigerated stock, record available temperature and time information, segregate potentially affected products and obtain a product-specific disposition decision before use. A normal appearance cannot establish preserved potency. Communicate delays and alternatives clearly, especially where missed therapy could cause immediate harm. Keep a record of affected inventory, decisions and handoffs. Infection prevention and safe staffing remain necessary when normal workflow is disrupted.
Worked example: A power outage stops dispensing and leaves a refrigerator temperature record incomplete. The pharmacist secures the pharmacy, identifies patients due for essential therapy and arranges an appropriate alternate supply route. Staff quarantine the affected stock and collect available time and temperature data. The pharmacist obtains a documented product disposition decision before any release and tells waiting patients when and where safe supply can be obtained.
Watch the distinction: Releasing refrigerated stock because it still feels cool confuses touch with evidence of stability. Hold uncertain product while arranging safe continuity of treatment.
Professionalism
53. Check authority before acting
Clinical suitability and legal authority are separate checks. A renewal may be sensible for a stable patient yet fall outside a pharmacist's authority in a particular jurisdiction or fail a local condition. Read the case's applicable rule, identify the permitted medicine and circumstances, and check whether the patient meets them. Then assess the indication, current use, benefit, adverse effects, relevant monitoring and any new symptoms before deciding. Document the basis for the action and communicate with the usual prescriber as required. If the renewal cannot be made, arrange a timely authorized route that addresses the risk of interruption. The PEBC pharmacist blueprint includes legislative and regulatory judgment; it does not grant a single nationwide prescribing scope.
Worked example: Assume a stated provincial rule allows a pharmacist to renew a stable chronic prescription when the original order remains eligible and a patient assessment supports continuation. A patient requests renewal but reports new dizziness after a dose change. Although the order is eligible, stability is uncertain. The pharmacist assesses symptoms and medicine use, contacts the prescriber for a revised plan and explains how an interruption will be managed lawfully.
Watch the distinction: Treating permission to renew as a duty to renew skips the clinical assessment. Authority sets what may be done; patient-specific safety determines whether it should be done.
54. Protect privacy in routine care
Privacy decisions start with the recipient, purpose and authority to receive information. A caller's knowledge of a patient's name or medicine does not establish consent. Verify identity through an appropriate process and determine whether the patient authorized disclosure or another applicable basis permits it. Even when sharing is allowed, limit the content to what is needed for the purpose. A family relationship alone does not make an adult patient's medication record available. If authority is absent, give a courteous general response without confirming or denying treatment and offer a path for the patient to contact the pharmacy or provide consent. Record significant disclosure decisions according to the practice setting. Apply the relevant provincial or territorial privacy requirements rather than assuming one rule fits every case.
Worked example: A caller says their adult sibling may be taking an antidepressant and asks for the name and dose. The pharmacist verifies the caller's identity but finds no authority to disclose the record. They do not confirm whether the sibling is a patient or takes the medicine. They invite the sibling to contact the pharmacy directly or provide appropriate consent for future communication.
Watch the distinction: Verifying who the caller is does not prove they may receive information. Identity and authority are different questions, especially for an adult patient's relative.
55. Obtain meaningful consent
Meaningful consent is an informed, voluntary choice about a specific service. Explain why a point-of-care test is proposed, what sample or procedure it involves, material discomfort or risks, and what a positive, negative or uncertain result can and cannot establish. Describe how the result will affect the care plan, who will receive it and what alternatives are available, including declining the test. Use language the patient understands and invite questions; a signature or nod alone does not show comprehension. Confirm the service is authorized in the stated jurisdiction and that the pharmacist can act appropriately on the result. If the patient declines, respect the choice and agree on another safe route to assessment. Document consent and the resulting decision.
Worked example: Assume the case's province permits the pharmacist to perform the proposed point-of-care test. A patient asks whether the test will diagnose the cause of every symptom. The pharmacist explains its limited purpose, sampling process, possible discomfort and how results will be shared. After the patient describes those limits back and agrees, the pharmacist performs the test; if they decline, the pharmacist offers an appropriate alternative assessment route.
Watch the distinction: Obtaining a signature before explaining the test does not establish informed consent. The patient needs its purpose, limits and choices in terms they can understand.
56. Manage a conflict of interest
A financial incentive can distort a recommendation even when the promoted product is clinically acceptable. Identify the patient's indication, desired effect, allergies, practical ability to use the product and total cost. Compare suitable options on those factors before considering brand preference. Disclose a relevant incentive or relationship in a way the patient can understand, and avoid steering the conversation through selective information. If a lower-cost generic has the same appropriate ingredient, strength and formulation for this patient, explain the equivalence relevant to the decision and ask about preference. If a patient-specific reason favours another product, record that reason. The test is whether the recommendation remains defensible without the incentive and preserves the patient's informed choice.
Worked example: A pharmacy offers staff a higher incentive for a promoted brand. A patient needs the medicine, and an equally suitable generic in the same formulation costs less. The pharmacist explains the options and relevant financial interest, recommends the generic because it meets the patient's needs at lower cost, and invites the patient's preference. The chosen product is checked against the prescription before dispensing.
Watch the distinction: Assuming a promoted product is acceptable because it works ignores the influence of price and incentives. Compare suitable choices and disclose interests that could affect trust.
57. Respect a patient's boundaries
Professional boundaries keep clinical judgment focused on the patient's needs and make care fair across patients. A gift may be intended as gratitude, yet its value, timing or expectation of special access can complicate the relationship. Respond warmly and clearly: acknowledge the gesture, explain that accepting an expensive personal gift is inappropriate under the applicable professional rules, and continue ordinary care. Consider whether a modest shared token is handled differently by the workplace, but do not improvise an exception under pressure. If the offer signals dependency or a wish for contact outside care, clarify how the patient can obtain services through normal channels. Document or discuss a concerning boundary issue when necessary, while protecting the patient's dignity.
Worked example: After help resolving a medication problem, a patient offers the pharmacist an expensive watch and asks for a personal phone number. The pharmacist thanks them, declines the gift under the applicable rules and gives the pharmacy's usual contact route for future care. The pharmacist continues the patient's follow-up without special access and records the interaction if the boundary concern affects ongoing care.
Watch the distinction: Accepting a costly gift because the patient insists can create an expectation of preferential treatment. A respectful decline protects both the relationship and equitable care.
58. Provide culturally safe care
Culturally safe care requires attention to the patient's experience of the encounter, not assumptions about identity. Listen to the concern, acknowledge harm without disputing the account, and ask what would make today's care more workable. An Indigenous patient's experience may reflect broader histories of discrimination in health care, but their goals and preferences remain individual. Offer clear choices about who participates, how information is explained and how follow-up occurs. Check whether cost, transport, language or prior treatment is affecting access. Avoid asking the patient to educate staff while they are seeking care; use professional learning and system changes to address repeated barriers. Agree on a plan the patient accepts, confirm understanding and document practical preferences that improve continuity.
Worked example: An Indigenous patient says a previous clinic dismissed their concerns and they hesitate to return. The pharmacist acknowledges the experience, asks what would help them feel safe today and listens without interruption. The patient prefers written medicine instructions and a telephone follow-up. The pharmacist provides the instructions, confirms the chosen contact method and arranges a service the patient is willing to approach if further assessment is needed.
Watch the distinction: Assuming a patient's preferences from their identity replaces listening with a stereotype. Ask what this person needs and change the care process accordingly.
59. Respond to a medication incident
A medication incident needs immediate clinical management and a separate process for honest disclosure and learning. Determine what medicine and strength the patient received, how much was taken, when, and whether symptoms or interacting conditions increase harm. Provide urgent assessment when indicated, correct the active therapy and give the patient clear instructions. Explain what happened factually, including what is known and what remains under review, and notify other clinicians involved in the patient's care. Record the event and make the required incident report. Later, examine system contributors such as look-alike packaging, selection steps, workload or verification gaps. A near miss that was caught before reaching the patient follows a different clinical response, though it can still reveal a process weakness.
Worked example: A patient prescribed 5 mg tablets received 10 mg tablets and took one dose. The pharmacist confirms the drug, time taken, other medicines and symptoms, assesses for dose-related harm and arranges urgent evaluation if needed. They tell the patient and prescriber what occurred, secure the incorrect supply, provide the verified product and instructions, then document and report the incident and review how the strength was selected.
Watch the distinction: Replacing the bottle quietly addresses future doses but leaves possible harm from the dose already taken. Assess, disclose and document before focusing on process improvement.
60. Reduce high-alert process risk
High-alert medicines deserve a check designed around the error that could cause harm. For insulin, separate the ordered dose in units from the vial concentration in units per millilitre and from the device's markings. Convert only when a volume is genuinely needed: volume equals ordered units divided by concentration. Check the insulin name, concentration, route, timing and delivery device against the verified order and patient regimen. Use a device calibrated for the intended insulin concentration whenever possible; a volume calculation does not authorize substituting an unsuitable syringe. An independent check should repeat the calculation and product comparison without relying on the first person's answer. Before release or administration, confirm the patient can identify and use the correct device and understands the dose in units.
Worked example: In a hypothetical order, the verified dose is 18 units from a vial labelled 100 units/mL. The required volume is 18 units ÷ 100 units/mL = 0.18 mL. A compatible insulin syringe marked in units should be set to 18 units; its marking must not be read as 18 mL. A second professional independently checks the vial concentration, order, device and patient instructions before release.
Watch the distinction: Writing 0.18 mL on the label as though it were the patient's usual dose invites device errors. State insulin doses in units and verify the matching device.
Official references and further reading
- PEBC complete current May 2026 pharmacist qualifying-exam blueprint with separate MCQ/OSCE weights
- NAPRA complete 2024 entry-to-practice professional competencies with pharmacist/technician columns preserved
- PEBC current blueprint interpretation and Canadian pharmacist scope
- PEBC current Part II interactive/non-interactive OSCE formats and supplied references
- PEBC current Part II seven-minute station timing and response rules